Promentis Pharmaceuticals, a Milwaukee company co-founded by Drs. John Mantsch and David Baker, researchers from the Marquette University College of Health Sciences, raised $26 million, including $17.2 million in its third funding round.
The investment will finance key clinical trials of Promentis’ most promising compound targeting neuropsychiatric disorders.
In collaboration with the School of Dentistry, the Biomedical Sciences Pre-dental program, or BMPD, will begin taking applications in the spring for a June 2017 launch.
The 12-month program is for students with a bachelor’s degree who wish to build their resumes through an intensive pre-dental curriculum that includes graduate-level biomedical coursework and immersion in the dental field.
Learn more about the BMPD